Literature DB >> 34998527

Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead.

Henning Willers1, Mechthild Krause2, Corinne Faivre-Finn3, Anthony J Chalmers4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34998527      PMCID： PMC9074417          DOI： 10.1016/j.ijrobp.2021.10.142

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   8.013


× No keyword cloud information.
  18 in total

1.  Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.

Authors:  Steven H Lin; Henning Willers; Sunil Krishnan; Jann N Sarkaria; Michael Baumann; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-25       Impact factor: 8.013

2.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

3.  PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice.

Authors:  Luiza Madia Lourenco; Yanyan Jiang; Neele Drobnitzky; Marcus Green; Fiona Cahill; Agata Patel; Yasmin Shanneik; John Moore; Anderson J Ryan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-11-06       Impact factor: 7.038

4.  Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.

Authors:  Sophia C Kamran; Beow Y Yeap; Christine A Ulysse; Catherine Cronin; Cynthia L Bowes; Brittany Durgin; Justin F Gainor; Melin J Khandekar; Joanna Y Tansky; Florence K Keane; Christine C Olsen; Henning Willers
Journal:  JAMA Oncol       Date:  2021-06-01       Impact factor: 31.777

5.  Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.

Authors:  Yanyan Jiang; Jennifer Martin; Maryam Alkadhimi; Kay Shigemori; Paul Kinchesh; Stuart Gilchrist; Veerle Kersemans; Sean Smart; James M Thompson; Mark A Hill; Mark J O'Connor; Barry R Davies; Anderson J Ryan
Journal:  Br J Cancer       Date:  2021-03-19       Impact factor: 7.640

6.  A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.

Authors:  Hao-Wen Sim; Kerrie L McDonald; Zarnie Lwin; Elizabeth H Barnes; Mark Rosenthal; Matthew C Foote; Eng-Siew Koh; Michael Back; Helen Wheeler; Erik P Sulman; Michael E Buckland; Lauren Fisher; Robyn Leonard; Merryn Hall; David M Ashley; Sonia Yip; John Simes; Mustafa Khasraw
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

7.  Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

Authors:  Fiona A Dungey; Dana A Löser; Anthony J Chalmers
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-15       Impact factor: 7.038

8.  Screening and Validation of Molecular Targeted Radiosensitizers.

Authors:  Henning Willers; Xiao Pan; Nathalie Borgeaud; Irina Korovina; Lydia Koi; Regina Egan; Patricia Greninger; Aliza Rosenkranz; Jong Kung; Andrew S Liss; Leslie A Parsels; Meredith A Morgan; Theodore S Lawrence; Steven H Lin; Theodore S Hong; Beow Y Yeap; Lori J Wirth; Aaron N Hata; Christopher J Ott; Cyril H Benes; Michael Baumann; Mechthild Krause
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-31       Impact factor: 7.038

9.  Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Authors:  David E Kozono; Thomas E Stinchcombe; Joseph K Salama; Jeffrey Bogart; W Jeffrey Petty; Michael J Guarino; Lyudmila Bazhenova; James M Larner; Jared Weiss; Thomas A DiPetrillo; Steven J Feigenberg; Xin Chen; Zhaowen Sun; Silpa Nuthalapati; Lindsey Rosenwinkel; Eric F Johnson; Bruce A Bach; Yan Luo; Everett E Vokes
Journal:  Lung Cancer       Date:  2021-07-21       Impact factor: 5.705

Review 10.  Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.

Authors:  Paul Lesueur; François Chevalier; Jean-Baptiste Austry; Waisse Waissi; Hélène Burckel; Georges Noël; Jean-Louis Habrand; Yannick Saintigny; Florence Joly
Journal:  Oncotarget       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.